| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
|
|
|||||||||
|
|
Oncology-Clinical Diagnosis: Solid TumorsClinical Diagnosis-Solid Tumors Posters |
1 Nuclear Medicine; 2 Internal Medicine; 3 Surgery, Yeungnam University Hospital, Daegu, South Korea
1452
Objectives: Chemotherapy is currently used in patients with recurrent breast cancer. The aim of this study was to evaluate the availability of sequential F-18 FDG PET/CT to predict response after the third and sixth cycle of chemotherapy for recurrent breast cancer.
Methods: Nine patients( mean age 48.6 ±9.5 years old) with 39 lesions underwent serial F-18 FDG PET/CT examinations. F-18 FDG PET/CT images of each recurrent lesion were analyzed visual and semiquantitatively using maxSUV, before and after the 3rd and 6th cycle chemotherapy. Clinical response, as assessed by conventional imaging after completion of chemotherapy, served as reference.
Results: After completion of sixth cycle of chemotherapy, 4 patients responded. Before treatment, mean value of maxSUV of the responded (group A) and non-responded( group B) were 8.4 ± 3.2 and 10.1 ± 3.5, which there was statistically no significant difference between the two groups (p > 0.1). After the 3rd cycle chemotherapy, the lesions of group A(n=23) did not show hypermetabolism on visual anaysis(maxSUV <3), except only one lesion(maxSUV=6.1). However the lesions of group B (n=16) showed several hypermetabolic lesions (SUV > 3.0) after 3rd cycles chemotherapy. After the 6th cycle chemotherapy, having disappeared lesions of group A were still not seen and the only one lesion showed more decreased maxSUV(3.7). But the lesions of group B looked almost the same as after 3rd cycle chemotherapy(p > 0.6), what was worse, new lesions developed.
Conclusions: This preliminary observation suggests that the serial follow-up using F-18 FDG PET/CT is available to predict response to chemotherapy in recurrent breast cancer patients.
| ||||||||||||||||||||||||||||||||||||||
